BioSpace

FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease

The approval of Mirum Pharmaceuticals’ ALK2 inhibitor for fibrodysplasia ossificans progressiva on Friday adds a third option for patients who had long been without any treatments, joining Regeneron’s recently approved Pasatru and Ipsen’s Sohonos.

By BioSpace

1 min read
FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease
FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights